Understand the source comparison
Peptides Help with Depression: Research vs Regulatory Reality
Cerebrolysin BDNF upregulation, synaptic repair Multiple Phase 3 trials (post-stroke depression) Not approved in the U.S. Most evidence exists for this compound. Used clinically in Europe and Asia Dihexa HGF/Met receptor activation, synaptogenesis Phase 1 safe
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin
- BDNF upregulation, synaptic repair
- Multiple Phase 3 trials (post-stroke depression)
- Not approved in the U.S.
- Most evidence exists for this compound. Used clinically in Europe and Asia
- Dihexa
- HGF/Met receptor activation, synaptogenesis
- Phase 1 safety only
- None
- Potent preclinical effects but zero psychiatric trial data
- P21
- CNTF-derived neuroplasticity modulation
- Preclinical only
- Promising animal data. Completely unvalidated in humans
- Thymalin
- HPA axis regulation, immune modulation
- Observational studies only
- Indirect mood effects via stress response. Not a direct antidepressant
- Selank
- Enkephalin analog, anxiolytic effect
- Phase 2 trials (anxiety, not depression)
- Anxiolytic data exists. Antidepressant claims are extrapolation
- The regulatory gap is the critical issue. Even Cerebrolysin, which has the strongest clinical evidence, isn't FDA-approved for any psychiatric indication in the United States. It's approved in several European and Asian countries for cognitive impairment and stroke recovery. But importing it for off-label psychiatric use places the burden of risk entirely on the patient and prescriber.